Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Entrada Therapeutics, Inc.

Contributing Author

Recent Articles by Entrada Therapeutics, Inc.

Sep-10
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program TRDA -9.70% GlobeNewswire
Sep-02
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
Aug-05
Entrada Therapeutics Reports Second Quarter 2026 Financial Results TRDA GlobeNewswire
Jun-02
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study TRDA GlobeNewswire
Jun-01
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
May-07
Entrada Therapeutics Reports First Quarter 2026 Financial Results TRDA -57.27% GlobeNewswire
May-07
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study TRDA -57.27% GlobeNewswire
May-06
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 TRDA GlobeNewswire
Mar-02
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
Feb-26
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results TRDA +6.76% GlobeNewswire
Feb-17
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study TRDA GlobeNewswire
Feb-04
Entrada Therapeutics to Present at Upcoming Investor Conferences TRDA -8.23% GlobeNewswire
Jan-08
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases TRDA GlobeNewswire
Dec-17
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference TRDA GlobeNewswire
Dec-04
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
Nov-06
Entrada Therapeutics Reports Third Quarter 2025 Financial Results TRDA GlobeNewswire
Oct-28
Entrada Therapeutics to Present at Upcoming Investor Conferences TRDA GlobeNewswire
Sep-05
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program TRDA GlobeNewswire
Sep-02
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
Aug-06
Entrada Therapeutics Reports Second Quarter 2025 Financial Results TRDA GlobeNewswire
Jun-03
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors TRDA GlobeNewswire
Jun-02
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA +7.11% GlobeNewswire
May-28
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping TRDA GlobeNewswire
May-08
Entrada Therapeutics Reports First Quarter 2025 Financial Results TRDA +5.64% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)